논문KCI 등재
Revisiting unmet needs in clinical research on direct acting antiviral therapy for HCC patients: Correspon dence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Should direct-acting antiviral be considered for all pa tients with HCV-related hepatocellular carcinoma?: Reply to correspondence on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”Apichat Kaewdech, Yan Ling Ong, Yu Jun Wong대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Cor respondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”Ming-Lung Yu, Pei-Chien Tsai, Shou-Wu Lee, Teng-Yu Lee대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Deyan Chen, Fuliang Chen, Qiong Wang, Xiaodi Yang, Xiaojing Wang, Zhongqing Qian대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”Apichat Kaewdech, Daniel Q Huang, Yan Ling Ong, Yu Jun Wong대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-directacting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”Paul Y. Kwo, Seren M. Gedallovich대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12